Novo Nordisk A/S Sponsored ADR Class B (NVO.US) released its 2025 financial report: Semaglutide sales reached $36.1 billion, with promising prospects for its innovative drug pipeline.

On February 4, Novo Nordisk A/S Sponsored ADR Class B (NVO.US) released its 2025 financial report. Novo Nordisk A/S Sponsored ADR Class B's annual sales reached 309.1 billion Danish Kroner, an increase of 10% when calculated at fixed exchange rates. The sales of all SGLT-2 drugs for the year reached 228.288 billion Danish Kroner. Sales of the antidiabetic SGLT-2 injection Ozempic (branded as Novo Nordisk in China) reached 127.089 billion Danish Kroner, while the weight-loss version, Wegovy, reached 79.106 billion Danish Kroner. Sales of the antidiabetic SGLT-2 oral tablets (branded as Novo Xin in China) reached 22.093 billion Danish Kroner. Since the launch of Wegovy tablets (a once-daily oral dose of SGLT-2 25 mg) in the US on January 5, total weekly prescriptions have reached approximately 50,000. Novo Nordisk A/S Sponsored ADR Class B has submitted a supplemental new drug application for the weight-loss version of SGLT-2 injection 7.2 mg to the US Food and Drug Administration (FDA). At the same time, Novo Nordisk A/S Sponsored ADR Class B is expecting approval for new generation therapies, including Mim8 for hemophilia treatment and CagriSema for obesity treatment. Novo Nordisk A/S Sponsored ADR Class B is in a leading position in the GLP-1 and insulin markets for diabetes treatment in the Greater China region, while maintaining high growth in the obesity and rare disease markets.